Understanding different facets of cardiovascular diseases based on model systems to human studies: A proteomic and metabolomic perspective

Journal of Proteomics

Volumn 127, Issue , 2015, Pages 50-60

  Basak, Trayambak ^a,b   Varshney, Swati ^a,b   Akhtar, Shamima ^a   Sengupta, Shantanu ^a,b  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^b ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

Author keywords

Cardiomyopathy; Cardiovascular diseases; Mass spectrometry; Model system; Proteomics

Indexed keywords

BIOLOGICAL MARKER;

CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; HEART MUSCLE ISCHEMIA; HUMAN; MASS SPECTROMETRY; METABOLOMICS; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEOMICS; REVIEW; SYSTEMS BIOLOGY; ANIMAL; METABOLISM; PROCEDURES; TRENDS;

ANIMALS; BIOMARKERS; CARDIOVASCULAR DISEASES; HUMANS; METABOLOMICS; PROTEOMICS;

EID: 84943364783     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2015.04.027     Document Type: Review

References (108)

1. Rizza S., Copetti M., Rossi C., Cianfarani M.A., Zucchelli M., Luzi A., et al. Metabolomics signature improves the prediction of cardiovascular events in elderly subjects. Atherosclerosis 2014, 232:260-264.
2. Pagidipati N.J., Gaziano T.A. Estimating deaths from cardiovascular disease: a review of global methodologies of mortality measurement. Circulation 2013, 127:749-756.
3. Egan B.M., Lackland D.T. Strategies for cardiovascular disease prevention: importance of public and community health programs. Ethn Dis 1998, 8:228-239.
4. Hennekens C.H. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation 1998, 97:1095-1102.
5. John J.M., Bhatt D.L. Emerging risk factors for atherosclerosis. Indian Heart J 2007, 59:28-37.
6. Ghazalpour A., Bennett B., Petyuk V.A., Orozco L., Hagopian R., Mungrue I.N., et al. Comparative analysis of proteome and transcriptome variation in mouse. PLoS Genet 2011, 7:e1001393.
7. Hanash S. Disease proteomics. Nature 2003, 422:226-232.
8. Cordwell S.J., Edwards A.V., Liddy K.A., Moshkanbaryans L., Solis N., Parker B.L., et al. Release of tissue-specific proteins into coronary perfusate as a model for biomarker discovery in myocardial ischemia/reperfusion injury. J Proteome Res 2012, 11:2114-2126.
9. Kuhn E., Addona T., Keshishian H., Burgess M., Mani D.R., Lee R.T., et al. Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem 2009, 55:1108-1117.
10. Chapelle J.P. Cardiac troponin I and troponin T: recent players in the field of myocardial markers. Clin Chem Lab Med CCLM/FESCC 1999, 37:11-20.
11. Zimmermann-Ivol C.G., Burkhard P.R., Le Floch-Rohr J., Allard L., Hochstrasser D.F., Sanchez J.C. Fatty acid binding protein as a serum marker for the early diagnosis of stroke: a pilot study. Mol Cell Proteomics 2004, 3:66-72.
12. Kleine A.H., Glatz J.F., Van Nieuwenhoven F.A., Van der Vusse G.J. Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man. Mol Cell Biochem 1992, 116:155-162.
13. Ishikawa Y., Saffitz J.E., Mealman T.L., Grace A.M., Roberts R. Reversible myocardial ischemic injury is not associated with increased creatine kinase activity in plasma. Clin Chem 1997, 43:467-475.
14. Rezeli M., Vegvari A., Donnarumma F., Gidlof O., Smith J.G., Erlinge D., et al. Development of an MRM assay panel with application to biobank samples from patients with myocardial infarction. J Proteomics 2013, 87:16-25.
15. Westerterp M., Van Eck M., de Haan W., Offerman E.H., Van Berkel T.J., Havekes L.M., et al. Apolipoprotein CI aggravates atherosclerosis development in ApoE-knockout mice despite mediating cholesterol efflux from macrophages. Atherosclerosis 2007, 195:e9-e16.
16. Shachter N.S., Hayek T., Leff T., Smith J.D., Rosenberg D.W., Walsh A., et al. Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice. J Clin Invest 1994, 93:1683-1690.
17. Curtiss L.K. ApoE in atherosclerosis: a protein with multiple hats. Arterioscler Thromb Vasc Biol 2000, 20:1852-1853.
18. Yin X., Subramanian S., Hwang S.J., O'Donnell C.J., Fox C.S., Courchesne P., et al. Protein biomarkers of new-onset cardiovascular disease: prospective study from the systems approach to biomarker research in cardiovascular disease initiative. Arterioscler Thromb Vasc Biol 2014, 34:939-945.
19. Nigro P., Satoh K., O'Dell M.R., Soe N.N., Cui Z., Mohan A., et al. Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice. J Exp Med 2011, 208:53-66.
20. Hadjinicolaou A.V., Wu L., Fang B., Watson P.A., Hall F.C., Busch R. Relationship of CD146 expression to activation of circulating T cells: exploratory studies in healthy donors and patients with connective tissue diseases. Clin Exp Immunol 2013, 174:73-88.
21. Moulton K.S., Olsen B.R., Sonn S., Fukai N., Zurakowski D., Zeng X. Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis. Circulation 2004, 110:1330-1336.
22. Nijmeijer R., Lagrand W.K., Lubbers Y.T., Visser C.A., Meijer C.J., Niessen H.W., et al. C-reactive protein activates complement in infarcted human myocardium. Am J Pathol 2003, 163:269-275.
23. Schiavinato A., Becker A.K., Zanetti M., Corallo D., Milanetto M., Bizzotto D., et al. EMILIN-3, peculiar member of elastin microfibril interface-located protein (EMILIN) family, has distinct expression pattern, forms oligomeric assemblies, and serves as transforming growth factor beta (TGF-beta) antagonist. J Biol Chem 2012, 287:11498-11515.
24. Cubedo J., Padro T., Cinca J., Mata P., Alonso R., Badimon L. Retinol-binding protein 4 levels and susceptibility to ischaemic events in men. Eur J Clin Invest 2014, 44:266-275.
25. Lambadiari V., Kadoglou N.P., Stasinos V., Maratou E., Antoniadis A., Kolokathis F., et al. Serum levels of retinol-binding protein-4 are associated with the presence and severity of coronary artery disease. Cardiovasc Diabetol 2014, 13:121.
26. Jacquet S., Yin X., Sicard P., Clark J., Kanaganayagam G.S., Mayr M., et al. Identification of cardiac myosin-binding protein C as a candidate biomarker of myocardial infarction by proteomics analysis. Mol Cell Proteomics 2009, 8:2687-2699.
27. Kuster D.W., Cardenas-Ospina A., Miller L., Liebetrau C., Troidl C., Nef H.M., et al. Release kinetics of circulating cardiac myosin binding protein-C following cardiac injury. Am J Physiol Heart Circ Physiol 2014, 306:H547-H556.
28. Cieniewski-Bernard C., Mulder P., Henry J.P., Drobecq H., Dubois E., Pottiez G., et al. Proteomic analysis of left ventricular remodeling in an experimental model of heart failure. J Proteome Res 2008, 7:5004-5016.
29. Brixius K., Schwinger R.H., Hoyer F., Napp A., Renner R., Bolck B., et al. Isoform-specific downregulation of peroxiredoxin in human failing myocardium. Life Sci 2007, 81:823-831.
30. Zhang X., Min X., Li C., Benjamin I.J., Qian B., Ding Z., et al. Involvement of reductive stress in the cardiomyopathy in transgenic mice with cardiac-specific overexpression of heat shock protein 27. Hypertension 2010, 55:1412-1417.
31. Boixel C., Fontaine V., Rucker-Martin C., Milliez P., Louedec L., Michel J.B., et al. Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J Am Coll Cardiol 2003, 42:336-344.
32. Nagase H., Woessner J.F. Matrix metalloproteinases. J Biol Chem 1999, 274:21491-21494.
33. Wei Y., Cui C., Lainscak M., Zhang X., Li J., Huang J., et al. Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: relationship between MMP-10 and LV remodelling. J Cell Mol Med 2011, 15:773-782.
34. Scheler C., Li X.P., Salnikow J., Dunn M.J., Jungblut P.R. Comparison of two-dimensional electrophoresis patterns of heat shock protein Hsp27 species in normal and cardiomyopathic hearts. Electrophoresis 1999, 20:3623-3628.
35. Chugh S., Ouzounian M., Lu Z., Mohamed S., Li W., Bousette N., et al. Pilot study identifying myosin heavy chain 7, desmin, insulin-like growth factor 7, and annexin A2 as circulating biomarkers of human heart failure. Proteomics 2013, 13:2324-2334.
36. Miyata S., Minobe W., Bristow M.R., Leinwand L.A. Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res 2000, 86:386-390.
37. Samarel A.M. IGF-1 overexpression rescues the failing heart. Circ Res 2002, 90:631-633.
38. Camors E., Monceau V., Charlemagne D. Annexins and Ca2+ handling in the heart. Cardiovasc Res 2005, 65:793-802.
39. Banfi C., Brioschi M., Barcella S., Veglia F., Biglioli P., Tremoli E., et al. Oxidized proteins in plasma of patients with heart failure: role in endothelial damage. Eur J Heart Fail 2008, 10:244-251.
40. Mebazaa A., Vanpoucke G., Thomas G., Verleysen K., Cohen-Solal A., Vanderheyden M., et al. Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure. Eur Heart J 2012, 33:2317-2324.
41. Mair J., Friedl W., Thomas S., Puschendorf B. Natriuretic peptides in assessment of left-ventricular dysfunction. Scand J Clin Lab Invest Suppl 1999, 230:132-142.
42. Wang T.J., Gona P., Larson M.G., Tofler G.H., Levy D., Newton-Cheh C., et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006, 355:2631-2639.
43. Heeschen C., Dimmeler S., Hamm C.W., van den Brand M.J., Boersma E., Zeiher A.M., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003, 348:1104-1111.
44. Gururajan P., Gurumurthy P., Nayar P., Babu S., Sarasabharati A., Victor D., et al. Increased serum concentrations of soluble CD40 ligand as a prognostic marker in patients with acute coronary syndrome. Indian J Clin Biochem 2009, 24:229-233.
45. von zur Muhlen C., Schiffer E., Sackmann C., Zurbig P., Neudorfer I., Zirlik A., et al. Urine proteome analysis reflects atherosclerotic disease in an ApoE-/- mouse model and allows the discovery of new candidate biomarkers in mouse and human atherosclerosis. Mol Cell Proteomics 2012, 11. [M111 013847].
46. Zimmerli L.U., Schiffer E., Zurbig P., Good D.M., Kellmann M., Mouls L., et al. Urinary proteomic biomarkers in coronary artery disease. Mol Cell Proteomics 2008, 7:290-298.
47. Donahue M.P., Rose K., Hochstrasser D., Vonderscher J., Grass P., Chibout S.D., et al. Discovery of proteins related to coronary artery disease using industrial-scale proteomics analysis of pooled plasma. Am Heart J 2006, 152:478-485.
48. Tian H., Li C.S., Zhao K.W., Wang J.C., Duarte M.E., David C.L., et al. A carboxy terminal BMP/TGF-beta binding site in secreted phosphoprotein 24kD independently affects BMP-2 activity. J Cell Biochem 2015, 116:667-676.
49. Tang W.H., Wu Y., Nicholls S.J., Hazen S.L. Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease. Clin Chem 2011, 57:33-39.
50. van Eyken P., Sciot R., van Damme B., de Wolf-Peeters C., Desmet V.J. Keratin immunohistochemistry in normal human liver. Cytokeratin pattern of hepatocytes, bile ducts and acinar gradient. Virchows Arch A Pathol Anat Histopathol 1987, 412:63-72.
51. Shao B., Pennathur S., Heinecke J.W. Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions. J Biol Chem 2012, 287:6375-6386.
52. Jin X., Xia L., Wang L.S., Shi J.Z., Zheng Y., Chen W.L., et al. Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats. Proteomics 2006, 6:1948-1956.
53. Meng C., Jin X., Xia L., Shen S.M., Wang X.L., Cai J., et al. Alterations of mitochondrial enzymes contribute to cardiac hypertrophy before hypertension development in spontaneously hypertensive rats. J Proteome Res 2009, 8:2463-2475.
54. Zhou Y.C., Liu B., Li Y.J., Jing L.L., Wen G., Tang J., et al. Effects of buyang huanwu decoction on ventricular remodeling and differential protein profile in a rat model of myocardial infarction. Evid Based Complement Alternat Med 2012, 2012:385247.
55. Paulsson A.K., Franklin S., Mitchell-Jordan S.A., Ren S., Wang Y., Vondriska T.M. Post-translational regulation of calsarcin-1 during pressure overload-induced cardiac hypertrophy. J Mol Cell Cardiol 2010, 48:1206-1214.
56. Chowdhury D., Tangutur A.D., Khatua T.N., Saxena P., Banerjee S.K., Bhadra M.P. A proteomic view of isoproterenol induced cardiac hypertrophy: prohibitin identified as a potential biomarker in rats. J Transl Med 2013, 11:130.
57. Mitra A., Basak T., Ahmad S., Datta K., Datta R., Sengupta S., et al. Comparative proteome profiling during cardiac hypertrophy and myocardial infarction reveals altered glucose oxidation by differential activation of pyruvate dehydrogenase E1 component subunit beta. J Mol Biol 2015, 427:2104-2120.
58. Gramolini A.O., Kislinger T., Alikhani-Koopaei R., Fong V., Thompson N.J., Isserlin R., et al. Comparative proteomics profiling of a phospholamban mutant mouse model of dilated cardiomyopathy reveals progressive intracellular stress responses. Mol Cell Proteomics 2008, 7:519-533.
59. Rosello-Lleti E., Alonso J., Cortes R., Almenar L., Martinez-Dolz L., Sanchez-Lazaro I., et al. Cardiac protein changes in ischaemic and dilated cardiomyopathy: a proteomic study of human left ventricular tissue. J Cell Mol Med 2012, 16:2471-2486.
60. Hammer E., Goritzka M., Ameling S., Darm K., Steil L., Klingel K., et al. Characterization of the human myocardial proteome in inflammatory dilated cardiomyopathy by label-free quantitative shotgun proteomics of heart biopsies. J Proteome Res 2011, 10:2161-2171.
61. Heinke M.Y., Wheeler C.H., Yan J.X., Amin V., Chang D., Einstein R., et al. Changes in myocardial protein expression in pacing-induced canine heart failure. Electrophoresis 1999, 20:2086-2093.
62. Sawicki G., Jugdutt B.I. Detection of regional changes in protein levels in the in vivo canine model of acute heart failure following ischemia-reperfusion injury: functional proteomics studies. Proteomics 2004, 4:2195-2202.
63. Handley-Goldstone H.M., Grow M.W., Stegeman J.J. Cardiovascular gene expression profiles of dioxin exposure in zebrafish embryos. Toxicol Sci 2005, 85:683-693.
64. White M.Y., Cordwell S.J., McCarron H.C., Prasan A.M., Craft G., Hambly B.D., et al. Proteomics of ischemia/reperfusion injury in rabbit myocardium reveals alterations to proteins of essential functional systems. Proteomics 2005, 5:1395-1410.
65. Kim N., Lee Y., Kim H., Joo H., Youm J.B., Park W.S., et al. Potential biomarkers for ischemic heart damage identified in mitochondrial proteins by comparative proteomics. Proteomics 2006, 6:1237-1249.
66. Mitra A., Basak T., Datta K., Naskar S., Sengupta S., Sarkar S. Role of alpha-crystallin B as a regulatory switch in modulating cardiomyocyte apoptosis by mitochondria or endoplasmic reticulum during cardiac hypertrophy and myocardial infarction. Cell Death Dis. 2013, 4:e582.
67. Jing L., Parker C.E., Seo D., Hines M.W., Dicheva N., Yu Y., et al. Discovery of biomarker candidates for coronary artery disease from an APOE-knock out mouse model using iTRAQ-based multiplex quantitative proteomics. Proteomics 2011, 11:2763-2776.
68. de Roos B., Rucklidge G., Reid M., Ross K., Duncan G., Navarro M.A., et al. Divergent mechanisms of cis9, trans11-and trans10, cis12-conjugated linoleic acid affecting insulin resistance and inflammation in apolipoprotein E knockout mice: a proteomics approach. FASEB J 2005, 19:1746-1748.
69. Riwanto M., Rohrer L., Roschitzki B., Besler C., Mocharla P., Mueller M., et al. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 2013, 127:891-904.
70. Agnetti G., Husberg C., Van Eyk J.E. Divide and conquer: the application of organelle proteomics to heart failure. Circ Res 2011, 108:512-526.
71. Husberg C., Agnetti G., Holewinski R.J., Christensen G., Van Eyk J.E. Dephosphorylation of cardiac proteins in vitro - a matter of phosphatase specificity. Proteomics 2012, 12:973-978.
72. Kotlo K., Johnson K.R., Grillon J.M., Geenen D.L., deTombe P., Danziger R.S. Phosphoprotein abundance changes in hypertensive cardiac remodeling. J Proteomics 2012, 77:1-13.
73. Zhang J., Guy M.J., Norman H.S., Chen Y.C., Xu Q., Dong X., et al. Top-down quantitative proteomics identified phosphorylation of cardiac troponin I as a candidate biomarker for chronic heart failure. J Proteome Res 2011, 10:4054-4065.
74. Yuan C., Guo Y., Ravi R., Przyklenk K., Shilkofski N., Diez R., et al. Myosin binding protein C is differentially phosphorylated upon myocardial stunning in canine and rat hearts - evidence for novel phosphorylation sites. Proteomics 2006, 6:4176-4186.
75. Hoshino A., Okawa Y., Ariyoshi M., Kaimoto S., Uchihashi M., Fukai K., et al. Oxidative post-translational modifications develop LONP1 dysfunction in pressure overload heart failure. Circ Heart Fail 2014, 7:500-509.
76. Zhang L., Chen C.L., Kang P.T., Garg V., Hu K., Green-Church K.B., et al. Peroxynitrite-mediated oxidative modifications of complex II: relevance in myocardial infarction. Biochemistry 2010, 49:2529-2539.
77. Zhang L., Kang P.T., Chen C.L., Green K.B., Chen Y.R. Oxidative modifications of mitochondria complex II. Methods Mol Biol 2013, 1005:143-156.
78. Yar S., Monasky M.M., Solaro R.J. Maladaptive modifications in myofilament proteins and triggers in the progression to heart failure and sudden death. Pflugers Arch Eur J Physiol 2014, 466:1189-1197.
79. Behring J.B., Kumar V., Whelan S.A., Chauhan P., Siwik D.A., Costello C.E., et al. Does reversible cysteine oxidation link the Western diet to cardiac dysfunction?. FASEB J 2014, 28:1975-1987.
80. Simm A. Protein glycation during aging and in cardiovascular disease. J Proteomics 2013, 92:248-259.
81. Beltran-Alvarez P., Tarradas A., Chiva C., Perez-Serra A., Batlle M., Perez-Villa F., et al. Identification of N-terminal protein acetylation and arginine methylation of the voltage-gated sodium channel in end-stage heart failure human heart. J Mol Cell Cardiol 2014, 76:126-129.
82. Chan C.X., Khan A.A., Choi J.H., Ng C.D., Cadeiras M., Deng M., et al. Technology platform development for targeted plasma metabolites in human heart failure. Clin Proteomics 2013, 10:7.
83. Rennison J.H., Van Wagoner D.R. Impact of dietary fatty acids on cardiac arrhythmogenesis. Circ Arrhythm Electrophysiol 2009, 2:460-469.
84. Steffens D.C., Wei J., Krishnan K.R., Karoly E.D., Mitchell M.W., O'Connor C.M., et al. Metabolomic differences in heart failure patients with and without major depression. J Geriatr Psychiatry Neurol 2010, 23:138-146.
85. Calderon-Santiago M., Priego-Capote F., Galache-Osuna J.G., Luque de Castro M.D. Analysis of serum phospholipid profiles by liquid chromatography-tandem mass spectrometry in high resolution mode for evaluation of atherosclerotic patients. J Chromatogr A 2014, 1371:154-162.
86. Cole L.K., Dolinsky V.W., Dyck J.R., Vance D.E. Impaired phosphatidylcholine biosynthesis reduces atherosclerosis and prevents lipotoxic cardiac dysfunction in ApoE-/- mice. Circ Res 2011, 108:686-694.
87. Omori Y., Ohtani T., Sakata Y., Mano T., Takeda Y., Tamaki S., et al. l-Carnitine prevents the development of ventricular fibrosis and heart failure with preserved ejection fraction in hypertensive heart disease. J Hypertens 2012, 30:1834-1844.
88. Qiu Q., Li C., Wang Y., Xiao C., Li Y., Lin Y., et al. Plasma metabonomics study on Chinese medicine syndrome evolution of heart failure rats caused by LAD ligation. BMC Complement Altern Med 2014, 14:232.
89. Zhang H.Y., Chen X., Hu P., Liang Q.L., Liang X.P., Wang Y.M., et al. Metabolomic profiling of rat serum associated with isoproterenol-induced myocardial infarction using ultra-performance liquid chromatography/time-of-flight mass spectrometry and multivariate analysis. Talanta 2009, 79:254-259.
90. Liu Y.T., Jia H.M., Chang X., Cheng W.H., Zhao X., Ding G., et al. Metabolic pathways involved in Xin-Ke-Shu protecting against myocardial infarction in rats using ultra high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. J Pharm Biomed Anal 2014, 90:35-44.
91. Sansbury B.E., DeMartino A.M., Xie Z., Brooks A.C., Brainard R.E., Watson L.J., et al. Metabolomic analysis of pressure-overloaded and infarcted mouse hearts. Circ Heart Fail 2014, 7:634-642.
92. Gehmlich K., Dodd M.S., William Allwood J., Kelly M., Bellahcene M., Lad H.V., et al. Changes in the cardiac metabolome caused by perhexiline treatment in a mouse model of hypertrophic cardiomyopathy. Mol BioSyst 2015, 11:564-573.
93. Adams S.H., Hoppel C.L., Lok K.H., Zhao L., Wong S.W., Minkler P.E., et al. Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr 2009, 139:1073-1081.
94. Yucel D., Aydogdu S., Cehreli S., Saydam G., Canatan H., Senes M., et al. Increased oxidative stress in dilated cardiomyopathic heart failure. Clin Chem 1998, 44:148-154.
95. Alexander D., Lombardi R., Rodriguez G., Mitchell M.M., Marian A.J. Metabolomic distinction and insights into the pathogenesis of human primary dilated cardiomyopathy. Eur J Clin Invest 2011, 41:527-538.
96. Chrousos G.P. The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes. Int J Obes Relat Metab Disord 2000, 24(Suppl. 2):S50-S55.
97. Maekawa K., Hirayama A., Iwata Y., Tajima Y., Nishimaki-Mogami T., Sugawara S., et al. Global metabolomic analysis of heart tissue in a hamster model for dilated cardiomyopathy. J Mol Cell Cardiol 2013, 59:76-85.
98. Jain M., Brenner D.A., Cui L., Lim C.C., Wang B., Pimentel D.R., et al. Glucose-6-phosphate dehydrogenase modulates cytosolic redox status and contractile phenotype in adult cardiomyocytes. Circ Res 2003, 93:e9-e16.
99. Kolwicz S.C., Tian R. Glucose metabolism and cardiac hypertrophy. Cardiovasc Res 2011, 90:194-201.
100. Shah S.H., Bain J.R., Muehlbauer M.J., Stevens R.D., Crosslin D.R., Haynes C., et al. Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet 2010, 3:207-214.
101. Apostolov E.O., Ray D., Savenka A.V., Shah S.V., Basnakian A.G. Chronic uremia stimulates LDL carbamylation and atherosclerosis. J Am Soc Nephrol 2010, 21:1852-1857.
102. Valerio A., D'Antona G., Nisoli E. Branched-chain amino acids, mitochondrial biogenesis, and healthspan: an evolutionary perspective. Aging 2011, 3:464-478.
103. Turer A.T., Stevens R.D., Bain J.R., Muehlbauer M.J., van der Westhuizen J., Mathew J.P., et al. Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion. Circulation 2009, 119:1736-1746.
104. Luan H., Chen X., Zhong S., Yuan X., Meng N., Zhang J., et al. Serum metabolomics reveals lipid metabolism variation between coronary artery disease and congestive heart failure: a pilot study. Biomarkers 2013, 18:314-321.
105. Makrecka M., Kuka J., Volska K., Antone U., Sevostjanovs E., Cirule H., et al. Long-chain acylcarnitine content determines the pattern of energy metabolism in cardiac mitochondria. Mol Cell Biochem 2014, 395:1-10.
106. Lee J.Y., Sohn K.H., Rhee S.H., Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem 2001, 276:16683-16689.
107. Ganna A., Salihovic S., Sundstrom J., Broeckling C.D., Hedman A.K., Magnusson P.K., et al. Large-scale metabolomic profiling identifies novel biomarkers for incident coronary heart disease. PLoS Genet 2014, 10:e1004801.
108. Basak T., Varshney S., Hamid Z., Ghosh S., Seth S., Sengupta S. Identification of metabolic markers in coronary artery disease using an untargeted LC-MS based metabolomic approach. J Proteomics 2015, 127:170-178.